SUNRISE, FL / ACCESSWIRE / April 15, 2015 / Bioheart, Inc., a Florida Corporation (BHRT) announces today that it will hold a 1st Quarter Review Conference Call on Thursday, April 23rd, 2015 at 4:30 PM EDT. The call will highlight research and development, business and corporate accomplishments for the first quarter of 2015 and goals for the second quarter. Webinar and dial-in numbers for the conference call will be posted on Monday, April 20, 2015.
"We continue to advance on our plan and pathway to profitability," said Mike Tomas, President and Chief Executive Officer. "Each of our operating divisions: Bioheart, US Stem Cell Training, Vetbiologics and US Stem Cell Clinic have made strategic and tactical gains in the first quarter and we expect to build on our positive momentum as we continue through this year. We look forward to updating you on our accomplishments on April 23rd."
About Bioheart, Inc.
Bioheart, Inc. is an emerging enterprise in the regenerative medicine / cellular therapy industry. We are focused on the discovery, development and commercialization of cell based therapeutics that prevent, treat or cure disease by repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function. We believe that regenerative medicine / cellular therapeutics will play a large role in positively changing the natural history of diseases ultimately, we contend, lessening patient burdens as well as reducing the associated economic impact disease imposes upon modern society.
Our business includes the development of proprietary cell therapy products as well as revenue generating physician and patient based regenerative medicine / cell therapy training services, cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. Management maintains that revenues and their associated cash in-flows generated from our businesses will, over time, provide funds to support our clinical development activities as they do today for our general business operations. We believe the combination of our own therapeutics pipeline combined with our revenue generating capabilities provides the Company with a unique opportunity for growth and a pathway to profitability.
US Stem Cell Training, ("SCT"), an operating division of Bioheart, Inc., is a content developer of regenerative medicine / cell therapy informational and training materials for physicians and patients. SCT also provides in-person and online training courses which are delivered through in-person presentations at SCT’s state of the art facilities and globally at university, hospital and physician's office locations as well as through online webinars. Additionally, SCT provides hands-on clinical application training for physicians and health care professionals interested in providing regenerative medicine / cell therapy procedures.